… -weight heparin may attenuate cytokine storm in COVID-19 patients; therefore, low-molecular-weight
heparin could be a valid adjunctive therapeutic drug for the treatment of COVID-19 …

… Background: The treatment of COVID-19 patients with heparin is not always effective in
preventing thrombotic complications, but can also be associated with bleeding complications, …

… risk of venous thromboembolism in patients admitted to hospitals with COVID‐19. Clearly, …
In summary, there are several ways heparin can prove beneficial in patients with COVID‐19 …

… We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted
to … outcome was any thromboembolic complication, including venous thromboembolism (VTE), …

… One of these is the proper prevention and diagnosis of venous thromboembolism (VTE) and…
the use of heparins and the correct prevention and diagnosis of VTE in COVID-19 patients, …

… heparin to prevent thromboembolic events in COVID-19 [3, 4]. On the other hand, heparin
might … Still, it is unclear whether prophylactic heparin is associated with decreased COVID-19 …

… We found that the rate of thrombotic complications was higher with the use of therapeutic
compared with prophylactic LMWH (LMWH P = .051) and the same between prophylactic and …

… will focus on the thromboembolic events frequently observed in severe Covid-19 patients. It
… The diagnosis of this rare immune complication of heparin treatment may be difficult in Covid…

… for thromboprophylaxis in patients with COVID-19 is still lacking, … compare thromboembolic
outcomes of patients with COVID-19 … about heparin improvements of COVID-19 pneumonia …

… to be independent predictors of thrombotic complications. Two cases of DVT in COVID-19–affected
patients, despite prophylactic dosing of low molecular weight heparin (LMWH), have …